TABLE 1.
Cell cycle regulators or oncogenes
| Gene | Nuc IDa | Max fold changeb | Time (h) |
|---|---|---|---|
| 37-kDa leucine-rich repeat (LRR) protein | U32907 | ∼−4.6 | 24 |
| Absent in melanoma 1 (AIM1) | AI800499 | −7.4 | 20 |
| Activator of S-phase kinase | AB028069 | ∼9.2 | 18 |
| Acute myeloid leukemia (AML1) | M83215 | ∼−6 | 18 |
| Aryl hydrocarbon receptor | L19872 | 5 | 14 |
| AXL receptor tyrosine kinase | M76125 | −4.8 | 24 |
| Baculoviral IAP repeat-containing 5 (survivin) | U75285 | ∼−10.5 | 4 |
| BRCA1-associated protein 1 | AF045581 | ∼21.4 | 24 |
| BRCA2 region, mRNA sequence CG018 | U50527 | ∼6.2 | 8 |
| BTG family, member 3 | D64110 | 3.9 | 24 |
| Butyrate response factor 2 (epidermal growth factor response factor 2) | U07802 | −3.7 | 20 |
| cdc25 | S78187 | −4.6 | 16 |
| cdc2-related protein kinase mRNA | M68520 | ∼24 | 48 |
| CDC6 (cell division cycle 6, Saccharomyces cerevisiae) homolog | U77949 | ∼5.9 | 20 |
| Cdc6-related protein (HsCDC6) | U77949 | ∼5.9 | 20 |
| Cell division cycle 27 | AA166687 | ∼3.1 | 10 |
| Cell growth regulatory with ring finger domain | U66469 | 5.4 | 16 |
| c-fos | K00650 | ∼44.8 | 0.5 |
| Chediak-Higashi syndrome 1 | U67615 | −5.5 | 4 |
| c-kit | X06182 | ∼−3.2 | 48 |
| Coagulation factor II (thrombin) receptor | M62424 | −4.5 | 24 |
| Cyclin A1 | U66838 | 6.3 | 20 |
| Cyclin B | M25753 | ∼−15.4 | 1 |
| Cyclin D3 | M92287 | 4.2 | 24 |
| Cyclin E2 | AF091433 | 6.2 | 20 |
| Cyclin G1 | X77794 | −3.4 | 48 |
| Cyclin T2 | AF048731 | ∼−4.3 | 4 |
| Cyclin-dependent kinase inhibitor 1B (p27, Kip1) | AI304854 | −7 | 8 |
| Cyclin-selective ubiquitin carrier protein | U73379 | ∼−14.5 | 16 |
| Deleted in liver cancer 1 (dlc1) | AF035119 | −4.7 | 24 |
| Diphtheria toxin receptor | M60278 | ∼23.2 | 14 |
| Discs, large (Drosophila) homolog 1 | U13896 | ∼5.7 | 18 |
| E2F transcription factor 5, p130-binding | U31556 | ∼13.7 | 24 |
| E2F-5 | U31556 | 3.5 | 24 |
| EphB2 | AF025304 | 4.4 | 48 |
| Epithelial membrane protein 1 | Y07909 | −5.2 | 14 |
| ets variant gene 1 | U17163 | ∼−5.0 | 6 |
| Ets2 repressor factor | U15655 | 5.7 | 14 |
| Exostoses (multiple) 1 | S79639 | −7.1 | 48 |
| Fatty acid-binding protein 3, muscle and heart | AI041520 | ∼−4.6 | 18 |
| FBJ murine osteosarcoma viral oncogene homolog B | L49169 | 4.1 | 10 |
| Fibroblast growth factor 7 (keratinocyte growth factor) | M60828 | ∼−9.7 | 48 |
| Fibroblast growth factor receptor 3 | M64347 | ∼9.1 | 20 |
| Four and a half LIM domains 2 | U29332 | −5.4 | 24 |
| Gonadotropin-releasing hormone 1 | X01059 | ∼−6.4 | 6 |
| Growth arrest and DNA damage-inducible protein (gadd45) | M60974 | −3.3 | 6 |
| Growth arrest-specific 1 | L13698 | −3.8 | 6 |
| highly expressed in cancer, rich in leucine heptad repeats | AF017790 | −3.3 | 20 |
| homeo box A9 | U41813 | ∼−7.0 | 4 |
| IGF-II mRNA-binding protein 3 | U97188 | −3.7 | 14 |
| Interferon regulatory factor 4 | U52682 | ∼3.8 | 8 |
| Kinesin-like 1 | U37426 | −5.1 | 10 |
| Loss of heterozygosity, 11, chromosomal region 2, gene A | AI632589 | ∼−19.0 | 48 |
| MAD (mothers against decapentaplegic, Drosophila) homolog 3 | U68019 | −4.2 | 12 |
| Mad4 homolog | AF040963 | ∼−12.3 | 48 |
| Matrix metalloproteinase 11 (stromelysin 3) | X17610 | ∼−37.6 | 48 |
| MAX-binding protein | X96401 | −4.6 | 10 |
| MAX protein | AI693307 | ∼10.0 | 8 |
| Meis1 (mouse) homolog | U85707 | −9.1 | 48 |
| Melanoma antigen, family A, 2 | L18920 | ∼−10.4 | 1 |
| Menage a trois 1 (CAK assembly factor) | X87843 | ∼−5.0 | 4 |
| Neuropilin 1 | AF016050 | ∼−9.2 | 18 |
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) | X61498 | ∼9.4 | 24 |
| Oncogene Ret/Ptc, fusion activated | HG4679– HT5104 | ∼10.1 | 48 |
| Oncogene TC21 | AI365215 | −3.7 | 48 |
| p53 activated fragment 1 (WAF1) | U03106 | −4.4 | 48 |
| Peripheral myelin protein 22 | D11428 | −4 | 14 |
| Phorbol-12-myristate-13-acetate-induced protein 1 | D90070 | 17.2 | 10 |
a
Nuc ID, nucleotide sequence identification or sequence accession number.
b
Maximum (Max) fold change. A ∼ symbol in front of a fold change value indicates that the transcript was scored as absent in either the baseline or experimental sample and that the fold change was then calculated using the background noise value as the intensity for that comparison. The complete data set with difference calls can be accessed at http://www.molbio.princeton.edu/labs/shenk/browneetal2001/.